Locus licenses CRISPR tech to Janssen in potential $818m deal

    Beskrivelse

    Interview on 800 + USD Life Science deal in the CRISPR Antibiotics area

    Emne

    Antobiotic resistance, Phage therapy, CRISPR Cas 3. IP, Licensing

    Periode9 jan. 2019